false 0000873303 0000873303 2020-06-26 2020-06-26










Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2020


Sarepta Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)




215 First Street
Suite 415

Cambridge, MA 02142

(Address of principal executive offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (617) 274-4000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange on which registered

Common Stock, Par Value $0.0001 per share




The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 26, 2020, Sandesh Mahatme informed Sarepta Therapeutics, Inc. (the “Company”) of his resignation from his positions as the Company’s Executive Vice President, Chief Financial Officer and Chief Business Officer, effective as of July 10, 2020. Mr. Mahatme’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, financial statements, internal controls, policies or procedures. The Company thanks Mr. Mahatme for his substantial contributions during a transformational period for the Company and wishes him well in his future endeavors.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




Sarepta Therapeutics, Inc.





Date: June 30, 2020



/s/ Douglas S. Ingram




Douglas S. Ingram




President and Chief Executive Officer



Document and Entity Information
Jun. 26, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Entity Registrant Name Sarepta Therapeutics, Inc.
Entity Central Index Key 0000873303
Document Period End Date Jun. 26, 2020
Entity Emerging Growth Company false
Entity File Number 001-14895
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 93-0797222
Entity Address, Address Line One 215 First Street
Entity Address, Address Line Two Suite 415
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 274-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, Par Value $0.0001 per share
Trading Symbol SRPT
Name of each exchange on which registered NASDAQ